Oncologic Emergencies: Too Much Clotting—Venous Thromboembolism in Malignancy

Brit Long, Alex Koyfman

Research output: Contribution to journalArticle

Abstract

Background: Malignancy predisposes patients to higher risk of venous thromboembolism (VTE), which is the second leading cause of death in patients with cancer. Objective: This narrative review evaluates VTE in malignancy and the emergency medicine investigation and management of this patient population. Discussion: Patients with malignancy are at higher risk of VTE, including deep venous thrombosis (DVT) and pulmonary embolism (PE). Risk factors include the underlying cancer, other hematologic disorders, cancer therapies, and underlying comorbidities. While patients with malignancy and VTE can present similarly to those without malignancy, incidental VTE is more common in cancer patients. Existing scores such as the Wells and Revised Geneva score can assist in risk stratification in patients with malignancy. A negative D-dimer result in the appropriately risk-stratified patient can be used to exclude VTE, though D-dimer is more commonly elevated at baseline in patients with malignancy. Several scoring systems may be useful to predict recurrent risk of VTE, including the Khorana and Ottawa scores. Treatment includes anticoagulation with direct oral anticoagulants (DOACs) or low molecular weight heparin (LMWH). Outpatient therapy may be appropriate in select patients. Conclusions: This narrative review provides key updates in the assessment and management of cancer patients with VTE.

Original languageEnglish (US)
JournalJournal of Emergency Medicine
DOIs
StateAccepted/In press - Jan 1 2019

Fingerprint

Thromboembolism
Emergencies
Venous Thromboembolism
Neoplasms
Emergency Medicine
Low Molecular Weight Heparin
Pulmonary Embolism
Venous Thrombosis
Anticoagulants
Comorbidity
Cause of Death
Outpatients
Therapeutics

Keywords

  • anticoagulation
  • cancer
  • deep venous thrombosis
  • malignancy
  • pulmonary embolism
  • venous thromboembolism

ASJC Scopus subject areas

  • Emergency Medicine

Cite this

Oncologic Emergencies : Too Much Clotting—Venous Thromboembolism in Malignancy. / Long, Brit; Koyfman, Alex.

In: Journal of Emergency Medicine, 01.01.2019.

Research output: Contribution to journalArticle

@article{1a15463bac0e4dbfbc94ca99f9b46d9f,
title = "Oncologic Emergencies: Too Much Clotting—Venous Thromboembolism in Malignancy",
abstract = "Background: Malignancy predisposes patients to higher risk of venous thromboembolism (VTE), which is the second leading cause of death in patients with cancer. Objective: This narrative review evaluates VTE in malignancy and the emergency medicine investigation and management of this patient population. Discussion: Patients with malignancy are at higher risk of VTE, including deep venous thrombosis (DVT) and pulmonary embolism (PE). Risk factors include the underlying cancer, other hematologic disorders, cancer therapies, and underlying comorbidities. While patients with malignancy and VTE can present similarly to those without malignancy, incidental VTE is more common in cancer patients. Existing scores such as the Wells and Revised Geneva score can assist in risk stratification in patients with malignancy. A negative D-dimer result in the appropriately risk-stratified patient can be used to exclude VTE, though D-dimer is more commonly elevated at baseline in patients with malignancy. Several scoring systems may be useful to predict recurrent risk of VTE, including the Khorana and Ottawa scores. Treatment includes anticoagulation with direct oral anticoagulants (DOACs) or low molecular weight heparin (LMWH). Outpatient therapy may be appropriate in select patients. Conclusions: This narrative review provides key updates in the assessment and management of cancer patients with VTE.",
keywords = "anticoagulation, cancer, deep venous thrombosis, malignancy, pulmonary embolism, venous thromboembolism",
author = "Brit Long and Alex Koyfman",
year = "2019",
month = "1",
day = "1",
doi = "10.1016/j.jemermed.2019.08.010",
language = "English (US)",
journal = "Journal of Emergency Medicine",
issn = "0736-4679",
publisher = "Elsevier USA",

}

TY - JOUR

T1 - Oncologic Emergencies

T2 - Too Much Clotting—Venous Thromboembolism in Malignancy

AU - Long, Brit

AU - Koyfman, Alex

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Background: Malignancy predisposes patients to higher risk of venous thromboembolism (VTE), which is the second leading cause of death in patients with cancer. Objective: This narrative review evaluates VTE in malignancy and the emergency medicine investigation and management of this patient population. Discussion: Patients with malignancy are at higher risk of VTE, including deep venous thrombosis (DVT) and pulmonary embolism (PE). Risk factors include the underlying cancer, other hematologic disorders, cancer therapies, and underlying comorbidities. While patients with malignancy and VTE can present similarly to those without malignancy, incidental VTE is more common in cancer patients. Existing scores such as the Wells and Revised Geneva score can assist in risk stratification in patients with malignancy. A negative D-dimer result in the appropriately risk-stratified patient can be used to exclude VTE, though D-dimer is more commonly elevated at baseline in patients with malignancy. Several scoring systems may be useful to predict recurrent risk of VTE, including the Khorana and Ottawa scores. Treatment includes anticoagulation with direct oral anticoagulants (DOACs) or low molecular weight heparin (LMWH). Outpatient therapy may be appropriate in select patients. Conclusions: This narrative review provides key updates in the assessment and management of cancer patients with VTE.

AB - Background: Malignancy predisposes patients to higher risk of venous thromboembolism (VTE), which is the second leading cause of death in patients with cancer. Objective: This narrative review evaluates VTE in malignancy and the emergency medicine investigation and management of this patient population. Discussion: Patients with malignancy are at higher risk of VTE, including deep venous thrombosis (DVT) and pulmonary embolism (PE). Risk factors include the underlying cancer, other hematologic disorders, cancer therapies, and underlying comorbidities. While patients with malignancy and VTE can present similarly to those without malignancy, incidental VTE is more common in cancer patients. Existing scores such as the Wells and Revised Geneva score can assist in risk stratification in patients with malignancy. A negative D-dimer result in the appropriately risk-stratified patient can be used to exclude VTE, though D-dimer is more commonly elevated at baseline in patients with malignancy. Several scoring systems may be useful to predict recurrent risk of VTE, including the Khorana and Ottawa scores. Treatment includes anticoagulation with direct oral anticoagulants (DOACs) or low molecular weight heparin (LMWH). Outpatient therapy may be appropriate in select patients. Conclusions: This narrative review provides key updates in the assessment and management of cancer patients with VTE.

KW - anticoagulation

KW - cancer

KW - deep venous thrombosis

KW - malignancy

KW - pulmonary embolism

KW - venous thromboembolism

UR - http://www.scopus.com/inward/record.url?scp=85073554153&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85073554153&partnerID=8YFLogxK

U2 - 10.1016/j.jemermed.2019.08.010

DO - 10.1016/j.jemermed.2019.08.010

M3 - Article

C2 - 31627886

AN - SCOPUS:85073554153

JO - Journal of Emergency Medicine

JF - Journal of Emergency Medicine

SN - 0736-4679

ER -